Centrient Pharmaceuticals
Matthias Cools currently serves as a Member of The Supervisory Board and Director of Strategy and M&A at Centrient Pharmaceuticals since August 2020. Prior roles include Associate Director - Transactions Lead (M&A) and M&A specialist at UCB from September 2018 to August 2020, and Senior Advisor - Deal Advisory at KPMG Belgium from September 2014 to August 2018, where work involved financial due diligence, valuation, and business plan modeling across various sectors. Matthias began his professional career as an intern at Finindus and briefly worked as a Finance Assistant at Groep Sleuyter Real Estate. Educational credentials include a Master's in Financial Management from Vlerick Business School and a Master's in Applied Economics (Corporate Finance) from Ghent University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Centrient Pharmaceuticals
2 followers
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next generation statins and anti-fungals. We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as our own tablets, capsules and other finished dosage forms (FDFs). We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 1,800 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance. Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is owned by Bain Capital Private Equity, a leading global private investment firm.